Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LUCAR-DKS1
- Development stage
- Phase 1
- Lead developer
- Legend Biotech
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
LUCAR-DKS1 is a chimeric antigen receptor (CAR) natural killer (NK) cell therapy being developed for the treatment of relapsed or refractory autoimmune diseases[1][2][4][6]. The therapy involves engineering NK cells to express a CAR that targets disease-relevant antigens, enabling directed immune activity against pathogenic cells implicated in various autoimmune conditions. It is primarily developed by Legend Biotech, and clinical trials are currently evaluating its safety, tolerability, pharmacokinetics, and efficacy in adult patients with relapsed/refractory autoimmune diseases including systemic lupus erythematosus (SLE), systemic sclerosis (SSc), ANCA-associated vasculitis (AAV), idiopathic inflammatory myopathies (IIM), and Sjögren's syndrome (SjS)[2][4][6]. This therapy represents a novel, cell-based immunotherapy approach aimed at providing disease-modifying effects in severe autoimmunity.
- Brand names
- LUCAR-DKS1LUCAR-DKS-1LUCAR-DKS 1
- Other names
- LUCAR-DKS1LUCAR-DKS-1LUCAR-DKS 1
Beyond the preview
Go deeper on LUCAR-DKS1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LUCAR-DKS1.